The rise in the share price came after the company announced that its unit, Glenmark Therapeutics Inc, USA (Glenmark) has launched Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1 per cent.
| Subscribe To Our Free Newsletter |
The Most Valuable Commodity Is Information!
